Rania G Abdel-Latif

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4201228/publications.pdf

Version: 2024-02-01

932766 1125271 13 326 10 13 citations g-index h-index papers 13 13 13 404 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Preparation and Evaluation of Atorvastatin-Loaded Nanoemulgel on Wound-Healing Efficacy. Pharmaceutics, 2019, 11, 609.	2.0	67
2	Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative–inflammatory–apoptotic pathway. Fundamental and Clinical Pharmacology, 2020, 34, 548-558.	1.0	59
3	Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia/reperfusion injury through HIF-1α/VEGF signaling pathway. Archives of Pharmacal Research, 2020, 43, 514-525.	2.7	47
4	Nephroprotective effect of exogenous hydrogen sulfide donor against cyclophosphamide-induced toxicity is mediated by Nrf2/HO-1/NF-κB signaling pathway. Life Sciences, 2021, 264, 118630.	2.0	28
5	Sildenafil protects against nitric oxide deficiency-related nephrotoxicity in cyclosporine A treated rats. European Journal of Pharmacology, 2013, 705, 126-134.	1.7	26
6	Lixisenatide, a novel GLP-1 analog, protects against cerebral ischemia/reperfusion injury in diabetic rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 705-717.	1.4	25
7	TLRs-JNK/ NF-ΰB Pathway Underlies the Protective Effect of the Sulfide Salt Against Liver Toxicity. Frontiers in Pharmacology, 2022, 13, 850066.	1.6	23
8	Lixisenatide ameliorates cerebral ischemia-reperfusion injury via GLP-1 receptor dependent/independent pathways. European Journal of Pharmacology, 2018, 833, 145-154.	1.7	13
9	Modulation of eNOS/iNOS by nebivolol protects against cyclosporine A-mediated nephrotoxicity through targeting inflammatory and apoptotic pathways. Environmental Toxicology and Pharmacology, 2019, 69, 26-35.	2.0	12
10	Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats. Life Sciences, 2020, 263, 118592.	2.0	12
11	Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of highâ€fat dietâ€induced nonalcoholic fatty liver in rats. Fundamental and Clinical Pharmacology, 2020, 34, 353-364.	1.0	6
12	Statin therapy and SAR-COV-2: an available and potential therapy?. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 333-334.	1.4	5
13	Combined treatments with metformin and phosphodiesterase inhibitors alleviate nonalcoholic fatty liver disease in high-fat diet fed rats: a comparative study. Canadian Journal of Physiology and Pharmacology, 2020, 98, 498-505.	0.7	3